Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.
Conditions
Interventions
- RADIATION: Stereotactic body radiotherapy
Sponsor
University Hospital, Ghent